Cumulus Secures £3.25M to Revolutionize Neuroscience Trials With EEG Technology

The NeuLogiq platform was built with input from ten leading biopharma companies. It solves key problems in traditional brain assessments by offering objective data across various brain functions.

CEO Tina Sampath explains that most neuroscience studies still rely on outdated pen-and-paper tests, which don’t provide clear insights into brain activity—something NeuLogiq aims to fix.

"Biopharma companies need objective data to effectively establish baseline information about whether a drug is engaging with the region of the brain that it is targeting, whether a drug is effective, and to inform which cohort of patients may benefit the most from a particular drug.

The NeuLogiq Platform offers biopharma partners and collaborators a suite of state-of-the-art tools to advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions."

Cumulus Neuroscience’s platform uses a unique dry-sensor EEG headset (FDA-cleared in 2023) and tablet-based tests to track brain function in areas like memory, mood, and language.

The headset works in clinics or at home, which is especially helpful for conditions like Alzheimer’s that make hospital visits difficult.

Read Also - Italian Hydrogen Company Tulum Energy Secures €22.9 Million In Seed Round

The £3.25M funding round was led by a £1.5M investment from Whiterock’s Growth Capital Fund, with additional backing from Clarendon Fund Managers (£1.25M), ACF Investors (£300K), and Co Fund NI (£200K).

David McCurley, Investment Director at Whiterock, confirmed the firm’s equity support.

"Cumulus's world-class technology holds immense potential to transform the understanding, monitoring, and treatment of neurological and psychiatric conditions.

In particular, Cumulus' work promises to revolutionise the diagnosis and treatment of diseases such as Alzheimer's, Parkinson's, and depression - conditions of growing global significance as the population ages."

The funding will be used to boost marketing efforts and expand the team by hiring key roles, including a Head of B2B Marketing, Sales Operations lead, and a Vice President of Business Development.

About Cumulus Neuroscience

Founded in 2015, Cumulus Neuroscience is building advanced tools to tackle major healthcare challenges in neurodegeneration and psychiatry. Its integrated biomarker platform delivers faster, more accurate data for clinical trials, helping partners speed up the development of effective CNS drugs and improve trial efficiency and evaluation in neuroscience.